Vertex Pharmaceuticals Incorporated (LON: 0QZU)
London flag London · Delayed Price · Currency is GBP · Price in USD
401.39
+10.75 (2.75%)
Dec 23, 2024, 7:12 PM BST

Vertex Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Cash & Equivalents
5,23910,36910,5046,7955,9883,109
Upgrade
Short-Term Investments
1,285849.2274.5729.9670.7698.97
Upgrade
Cash & Short-Term Investments
6,52511,21810,7797,5256,6593,808
Upgrade
Cash Growth
-45.30%4.08%43.24%13.01%74.85%20.20%
Upgrade
Accounts Receivable
1,7511,5631,4421,137885.4633.52
Upgrade
Receivables
1,7511,5631,4421,137885.4633.52
Upgrade
Inventory
1,080738.8460.6353.1280.8167.5
Upgrade
Prepaid Expenses
438.7537.6431.6442.1228.6195.79
Upgrade
Restricted Cash
8.9--5.10.78
Upgrade
Other Current Assets
1.686.1121.998.6799.73
Upgrade
Total Current Assets
9,80414,14413,2359,5618,1334,823
Upgrade
Property, Plant & Equipment
2,5141,4531,4561,4241,284833.28
Upgrade
Long-Term Investments
4,7782,596112.2---
Upgrade
Goodwill
1,0881,0881,0881,0021,0021,002
Upgrade
Other Intangible Assets
831.6839.9603.6400400400
Upgrade
Long-Term Deferred Tax Assets
2,3091,8121,247934.5882.81,191
Upgrade
Long-Term Deferred Charges
-58.940.2---
Upgrade
Other Long-Term Assets
916.1737.8369.4110.849.369.38
Upgrade
Total Assets
22,24022,73018,15113,43311,7528,318
Upgrade
Accounts Payable
395.8364.9303.9195155.187.61
Upgrade
Accrued Expenses
3,2202,5562,0031,4671,3011,045
Upgrade
Current Portion of Leases
71.283.789.480.252.950.3
Upgrade
Current Income Taxes Payable
-99.5123.3211.3104.272.29
Upgrade
Current Unearned Revenue
220170.3159.6171.7191.562.33
Upgrade
Other Current Liabilities
66.4273.262.516.57317.68
Upgrade
Total Current Liabilities
3,9733,5472,7422,1421,8781,335
Upgrade
Long-Term Leases
1,703724.7810.3887.2889.5622.87
Upgrade
Other Long-Term Liabilities
933.3877.7685.8303.3298275.53
Upgrade
Total Liabilities
6,6095,1504,2383,3333,0652,233
Upgrade
Common Stock
2.62.62.62.52.62.59
Upgrade
Additional Paid-In Capital
6,9067,4507,3876,8817,8947,938
Upgrade
Retained Earnings
8,69410,1426,5233,201858.7-1,853
Upgrade
Comprehensive Income & Other
28.8-14.30.815.9-68.5-1.97
Upgrade
Total Common Equity
15,63117,58013,91310,1008,6876,085
Upgrade
Shareholders' Equity
15,63117,58013,91310,1008,6876,085
Upgrade
Total Liabilities & Equity
22,24022,73018,15113,43311,7528,318
Upgrade
Total Debt
1,774808.4899.7967.4942.4673.17
Upgrade
Net Cash (Debt)
9,45412,9089,9916,5585,7173,135
Upgrade
Net Cash Growth
-26.62%29.19%52.36%14.71%82.34%21.45%
Upgrade
Net Cash Per Share
36.6449.5538.5625.2321.7012.03
Upgrade
Filing Date Shares Outstanding
257.53258.31257.09254.58259.96259.27
Upgrade
Total Common Shares Outstanding
257.74257.7257.01254.48259.89258.99
Upgrade
Working Capital
5,83110,59710,4937,4196,2563,488
Upgrade
Book Value Per Share
60.6568.2254.1339.6933.4223.50
Upgrade
Tangible Book Value
13,71115,65312,2218,6987,2854,683
Upgrade
Tangible Book Value Per Share
53.2060.7447.5534.1828.0318.08
Upgrade
Land
-33.133.133.133.1-
Upgrade
Buildings
-928.6903.1892.5876.1713.41
Upgrade
Machinery
-911.9788.6701605.3548.44
Upgrade
Leasehold Improvements
-474.6410.9363.5234.6175.77
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.